journal article·2026-01

MOF and COF-based drug delivery system for Parkinson's disease: Mechanism, future and development of artificial intelligence

Chunyue Shi, Yan Liang, Yusheng Wang, Xinyi Zhang, Aparna Kushwaha, Abhinav Kumar, Jun Wang, Qin Ouyang, Yong Huang

Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Covalent Organic Framework Applications · Parkinson's Disease Mechanisms and Treatments · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Label-free and highly selective MOFs-based dopamine detection in urine of Parkinson's patients10.1016/j.cej.2022.136371 ↗
2. Intelligent identification of cerebrospinal fluid for the diagnosis of parkinson's disease10.1021/acs.analchem.3c04849 ↗
3. COF-coated microelectrode for space-confined electrochemical sensing of dopamine in parkinson's disease model mouse brain10.1021/jacs.3c08256 ↗
4. A covalent organic frameworks based sensor for adsorptive stripping voltammetric detection of nanomolar dopamine in living mouse brain
5. Artificial intelligence-enabled detection and assessment of Parkinson's disease using multimodal data: a survey
6. AI-Driven advances in parkinson's disease neurosurgery: enhancing patient selection, trial efficiency, and therapeutic outcomes10.3390/brainsci15050494 ↗
7. Metal–organic frameworks: a future toolbox for biomedicine?10.1039/D0CS00883D ↗
8. In situ generated 2,5-pyrazinedicarboxylate and oxalate ligands leading to a Eu-MOF for selective capture of C2H2 from C2H2/CO210.1039/D4DT01168F ↗
9. B. R Bloem, M. S. Okun, C. Klein, Parkinson's disease, Lancet, 397(10291) 2284.10.1016/S0140-6736(21)00218-X ↗
10. MOF-based platforms on diabetic disease: advanced and prospect of effective diagnosing and therapy10.1016/j.reactfunctpolym.2025.106520 ↗
11. The role of dopamine pharmacotherapy and addiction-like behaviors in Parkinson's disease10.1016/j.pnpbp.2020.109942 ↗
12. A rapid method for the determination of dopamine in porcine muscle by pre-column derivatization and HPLC with fluorescence detection
13. Electrochemical detection of dopamine with negligible interference from ascorbic and uric acid by means of reduced graphene oxide and metals-NPs based electrodes10.1016/j.aca.2021.339124 ↗
14. Three-dimensional nitrogen-doped graphenebased metal-free electrochemical sensors for simultaneous determination of ascorbic acid, dopamine, uric acid, and acetaminophen10.1039/D0AN01912G ↗
15. A novel dopamine electrochemical sensor based on a β-cyclodextrin/Ni-MOF/glassy carbon electrode10.1016/j.microc.2023.109328 ↗
16. Tuning the CO2 selective adsorption performance in MOFs by incorporating functional groups on the isophthalate skeleton10.1016/j.jssc.2023.124461 ↗
17. An electrochemical wearable sensor for levodopa quantification in sweat based on a metal–organic framework/graphene oxide composite with integrated enzymes
18. Conductive metal−organic framework microelectrodes regulated by conjugated molecular wires for monitoring of dopamine in the mouse brain10.1021/jacs.2c07053 ↗
19. Multi-walled carbon nanotubes-metal–organic framework nanocomposite based sensor for the monitoring of multiple monoamine neurotransmitters in living cells10.1016/j.bioelechem.2024.108776 ↗
20. Electrochemical detection of dopamine and uric acid with annealed metal−organic Framework/MXene (CuO/C/Ti3C2Tx) nanosheet composites for neurotransmitter sensing10.1021/acsanm.5c01758 ↗
21. Reduced glutathione-modified electrode for the detection of Hydroxyl free radicals10.3390/bios13020254 ↗
22. Modified carbon paste electrode using MIL-101 (Fe) metal-organic framework and ionic liquid for ferrocene-mediated voltammetric determination of glutathione
23. Electrochemical oxidation of glutathione in the presence of tryptophan at carbon paste electrode modified with ni-zn-metal-organic Frameworks/Graphene oxide and ferrocene derivative10.1149/1945-7111/ad7984 ↗
24. Electrochemiluminescent aptamer-sensor for alpha synuclein oligomer based on a metal– organic framework10.1039/D0AN00169D ↗
25. Signal-on photoluminescent detection of dopamine with carbon dots-MnO2 nanosheets platform based on inner filter effect10.1016/j.dyepig.2020.108515 ↗
26. Dopamine sensing based on ultrathin fluorescent metal−organic nanosheets10.1021/acsami.0c13166 ↗
27. Fluorescence sensing probe based on functionalized mesoporous MOFs for non-invasive and detection of dopamine in human fluids10.1016/j.talanta.2024.126356 ↗
28. Tailoring a luminescent metal − organic framework precise inclusion of Pt-Aptamer nanoparticle for noninvasive monitoring Parkinson's disease10.1016/j.cej.2022.136009 ↗
29. Experimental and theoretical validations of a one-pot sequential sensing of Hg2+ and biothiols by a 3D Cu-based zwitterionic metal−organic framework10.1016/j.talanta.2019.120596 ↗
30. A Eu-MOF-Based fluorescent sensing probe for the detection of Tryptophan and Cu2+ in aqueous solutions10.1007/s10895-024-03633-9 ↗
31. Metal organic framework-based tricolor fluorescence imprinted sensor for rapid intelligent detection of homovanillic acid10.1016/j.microc.2023.108607 ↗
32. A recyclable luminescent MOF sensor for On-Site detection of Insecticide dinotefuran and anti-parkinson’s drug entacapone in various environmental and biological specimens10.1002/asia.202400377 ↗
33. Colorimetric detection of L-Dopa via anti-etching of Au nanorods catalyzed by an MIL-88A (Fe)-TMB System10.1039/D5AY00805K ↗
34. Dual-mode sensing platform based on an iodide ion synergistic covalent triazine frameworks (CTFs) for point-of-care testing (POCT) of acetylcholinesterase10.1016/j.aca.2025.343836 ↗
35. A dual-modality immunosensor for simple and reliable detection of nitrated alpha-synuclein in serum based on silver-coated MOF10.1007/s00604-023-05783-2 ↗
36. Neuropathology of parkinson disease10.1016/j.parkreldis.2017.07.033 ↗
37. Metal–organic frameworks (MOFs) as host materials for the enhanced delivery of biomacromolecular therapeutics10.1039/D1CC05157A ↗
38. Metal-Organic framework (MOF)-based drug/Cargo delivery and cancer therapy10.1002/adma.201606134 ↗
39. Copper ions and parkinson's disease: why is homeostasis So relevant?10.3390/biom10020195 ↗
40. Copper release by MOF-74(Cu): a novel pharmacological alternative to diseases with deficiency of a vital oligoelement10.1039/D3RA07109J ↗
41. Development of the design and synthesis of metal–organic frameworks (MOFs) – from large scale attempts, functional oriented modifications, to artificial intelligence (AI) predictions10.1039/D4CS00432A ↗
42. Archimedean heterologous helixes in Ti10Cd6-oxo nanoclusters: double-helical self-assembly and therapeutic application in Parkinson's disease10.1039/D4QI00890A ↗
43. NLRP3 inflammasome of microglia promotes A1 astrocyte transformation, neo-neuron decline and cognition impairment in endotoxemia10.1016/j.bbrc.2022.02.092 ↗
44. Bioinspired copper single-atom nanozyme as a superoxide dismutase-like antioxidant for sepsis treatment
45. Metal–organic framework based nanozyme system for NLRP3 inflammasome-mediated neuroinflammatory regulation in parkinson's disease
46. Bioinspired metal–organic framework nanozyme reinforced with thermosensitive hydrogel for regulating inflammatory responses in parkinson's disease10.1007/s12274-023-6304-8 ↗
47. Chiral metal-organic frameworks incorporating nanozymes as neuroinflammation inhibitors for managing Parkinson's disease10.1038/s41467-023-43870-3 ↗
48. The third wheel or the game changer? How AI could team up with neurologists in Parkinson's care10.1016/j.parkreldis.2025.107797 ↗
49. Reconfigurable neuromorphic computing using methyl-engineered one-dimensional covalent organic framework memristors10.1021/acs.nanolett.5c00890 ↗
50. Integrating humidity-resistant and colorimetric COF-on-MOF sensors with artificial intelligence assisted data analysis for visualization of volatile organic compounds sensing10.1002/advs.202411621 ↗
51. MOF and COF platforms toward kidney-disease: advanced nanovehicles for effective diagnosing and treatment10.1016/j.microc.2025.113534 ↗
52. Covalent self-assembled highly sensitive humidity sensing system with wireless communication for plant physiology perception under disease stress10.1016/j.cej.2025.164501 ↗
53. Hollow crystallization COF capsuled MOF hybrids depict serum metabolic profiling for precise early diagnosis and risk stratification of acute coronary syndrome10.1002/advs.202302109 ↗
54. Multi-responsive Cascade enzyme-like catalytic nanoassembly for ferroptosis amplification and nanozyme-assisted mild photothermal therapy10.1016/j.actbio.2024.08.036 ↗
55. Barriers in bone tumor treatment: the emerging role of drug delivery systems10.1007/s12032-025-02853-8 ↗
56. AI-Driven advances in parkinson's disease neurosurgery: enhancing patient selection, trial efficiency, and therapeutic outcomes10.3390/brainsci15050494 ↗
57. Nanomedicine in the face of parkinson's disease: from drug delivery systems to nanozymes10.3390/cells11213445 ↗
58. Postsynthetic functionalization of covalent organic frameworks for dual channel fluorescence diagnosis of two indicators related to Parkinson's disease10.1016/j.snb.2021.131297 ↗
59. Metal/Covalent-Organic frameworks-based electrochemical sensors for the detection of ascorbic acid, dopamine and uric acid10.1016/j.ccr.2023.215427 ↗
60. A covalent organic frameworks based sensor for adsorptive stripping voltammetric detection of nanomolar dopamine in living mouse brain10.1016/j.snb.2024.137037 ↗
61. Amyloid detection in neurodegenerative diseases using MOFs10.1039/D4TB00373J ↗
62. Dual enzyme-mimicking bimetallic MOF for selective SERS detection of L-DOPA in human serum based on cascade catalytic reaction10.1016/j.talanta.2025.128178 ↗
63. Computer vision uncovers three fundamental dimensions of levodopa-responsive motor improvement in Parkinson's disease10.1038/s41531-025-00999-w ↗
64. Levodopa in parkinson's disease: current status and future developments10.2174/1570159X15666170510143821 ↗
65. In-situ anchoring bimetallic nanoparticles on covalent organic framework as an ultrasensitive electrochemical sensor for levodopa detection10.1016/j.talanta.2020.122072 ↗
66. Current strategies to enhance delivery of drugs across the blood–brain barrier10.3390/pharmaceutics14050987 ↗
67. Engineered nanomaterials that exploit blood-brain barrier dysfunction for delivery to the brain10.1016/j.addr.2023.114820 ↗
68. Metal–Organic frameworks as efficient materials for drug delivery10.1002/anie.200601878 ↗
69. Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases10.1016/j.jconrel.2016.05.044 ↗
70. Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa10.1038/npp.2011.212 ↗
71. Phase I trial of hES cell-derived dopaminergic neurons for Parkinson's disease10.1038/s41586-025-08845-y ↗
72. Design strategies for improving the crystallinity of covalent organic frameworks and conjugated polymers: a review10.1039/D1MH00809A ↗
73. Covalent organic frameworks: recent progress in biomedical applications10.1021/acsnano.2c11346 ↗
74. Effect of replacing grass silage with red clover silage on nutrient digestion, nitrogen metabolism, and milk fat composition in lactating cows fed diets containing a 60:40 forage-to-concentrate ratio10.3168/jds.2013-7358 ↗
75. Phosphorylation of covalent organic framework nanospheres for inhibition of amyloid-β peptide fibrillation10.1039/D2SC00253A ↗
76. Delivery of small-molecule drugs and protein drugs by injectable acid-responsive self-assembled COF hydrogels for combinatorial lung cancer treatment10.1021/acsami.3c10074 ↗
77. Interaction between α-Synuclein and metal ions, still looking for a role in the pathogenesis of parkinson's disease10.1007/s12017-009-8082-1 ↗
78. Gene transfer into Humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction10.1056/NEJM199008303230904 ↗
79. Covalent organic framework nanoparticles for anti-tumor gene therapy10.1007/s11426-021-9998-x ↗
80. Dual regulation of the orderly aggregation of covalent organic frameworks at the molecular level and nanoscale to achieve efficient phototherapy and gene therapy10.1016/j.cej.2024.152163 ↗
81. A comprehensive framework for Parkinson's disease diagnosis using explainable artificial intelligence empowered machine learning techniques10.1016/j.aej.2024.07.106 ↗
82. Quantitative multi-metabolite imaging of Parkinson's disease using AI boosted molecular MRI
83. PIDGN: an explainable multimodal deep learning framework for early prediction of Parkinson's disease10.1016/j.jneumeth.2025.110363 ↗
84. Comparative validation of AI and non-AI methods in MRI volumetry to diagnose Parkinsonian syndromes10.1038/s41598-023-30381-w ↗
85. Artificial intelligence diagnosis of parkinson's disease from MRI scans
86. Externally validated deep learning model to identify prodromal Parkinson's disease from electrocardiogram10.1038/s41598-023-38782-7 ↗
87. Liquid-biopsy proteomics combined with AI identifies cellular drivers of eye aging and disease in vivo10.1016/j.cell.2023.09.012 ↗
88. Energy-confinement 3D flower-shaped cages for AI-Driven decoding of metabolic fingerprints in cardiovascular disease diagnosis10.1021/acsnano.4c14656 ↗
89. AI WALKUP: a computer-vision approach to quantifying MDS-UPDRS in parkinson's disease
90. Improving reliability of movement assessment in Parkinson's disease using computer vision-based automated severity estimation10.1177/1877718X241312605 ↗
91. Late feature fusion using neural network with voting classifier for Parkinson's disease detection10.1186/s12911-024-02683-0 ↗
92. Early detection of parkinson's disease using AI techniques and image analysis10.3390/diagnostics14232615 ↗
93. Predicting UPDRS in Parkinson's disease using ensembles of self-organizing map and neuro-fuzzy10.1186/s13677-024-00641-9 ↗
94. Federated learning for secure development of AI models for Parkinson's disease detection using speech from different languages
95. Synthetic data generation techniques for developing AI-based speech assessments for parkinson's disease (A comparative study)
96. Cognitive activity analysis of Parkinson's patients using artificial intelligence techniques10.1007/s10072-024-07734-y ↗
97. AI-Enabled conversational journaling for advancing parkinson's disease symptom tracking
98. A framework for integrating artificial intelligence for clinical care with continuous therapeutic monitoring10.1038/s41551-023-01115-0 ↗
99. Personalizing deep brain stimulation therapy for parkinson's disease with Whole- brain MRI radiomics and machine learning
100. AiCareGaitRehabilitation: multi-Modalities sensor data fusion for AI-IoT enabled realtime electrical stimulation device for pre-Fog and post-Fog to person with Parkinson's disease10.1016/j.inffus.2025.103155 ↗